anmelden
Director/PDMR Shareholding
DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the "Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 30 April 2024 Mr Bob Sutcliffe, tha Chairman, purchased a total of 100,000 Ordinary Shares in the Company at a price of 1.46p per share.
Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 933,386 Ordinary Shares representing 1.46% of the issued share capital of the Company.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Robert Sutcliffe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chairman | |||
| b) | Initial notification /Amendment | Initial | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | DXS INTERNATIONAL PLC | |||
| b) | LEI | 2138001R1KEUWTXEVJ44 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.33p each | |||
| Identification code | ISIN GB00B2Q6HZ92 | ||||
| b) | Nature of the transaction | Issue of new shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 1.46p | 100,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 30 April 2024 | |||
| f) | Place of the transaction | Aquis Stock Exchange | |||
The Directors of DXS International plc accept responsibility for this announcement.
Enquiries:
| David Immelman (Chief Executive) DXS International plc | 01252 719800 david@dxs-systems.com |
| Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS | |
| www.dxs-systems.co.uk |
| Corporate Advisor | |
| David Papworth City & Merchant | 0207 101 7676 |
| Corporate Broker | |
| Hybridan LLP Claire Louise Noyce | 020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
Ausgewählte Hebelprodukte auf DXS International
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DXS International
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle DXS International Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
DXS International Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DXS International nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.